Newell-Price Named Clinical Research Director at Sheffield Teaching Hospitals NHS Foundation Tru

He is a professor of endocrinology at the University of Sheffield, an honorary consultant physician at the same Trust, and a past-president of the Endocrine Society.

• The article announces the appointment of John Newell-Price, MD, PhD, FRCP, as Clinical Research Director at Sheffield Teaching Hospitals NHS Foundation Trust.
• The piece situates his professional remit within the Trust’s broader research and innovation ambitions, aligned with the 10 Year Health Plan for England and a strategy to harness new technologies, medicines, and innovations to support prevention and treatment of clinical conditions.

• Newell-Price’s clinical remit includes pituitary and adrenal disorders, genetic endocrine disease, and neuroendocrine tumors and cancer.
• His research program concentrates on glucocorticoid excess and deficiency, with described discoveries that have produced new paradigms for diagnosis and treatment in these areas.

Funding sources for this activity are noted as UK Research and Innovation (UKRI), industry, and charitable organizations.

• The report credits Newell-Price with helping to establish Sheffield as a world-leading, patient-centered clinical endocrine service in which clinical and translational research and innovation are embedded.
• He has led national efforts through NHS England and the Royal College of Physicians to set standards of care, and contributed to internationally adopted, evidence-based clinical practice guidelines.
• A key element of his envisioned role is co-leading the Clinical Research and Innovation Office (CRIO) as part of the Trust’s new research and innovation strategy.

The article acknowledges Heller’s leadership and contributions to advancing clinical research and innovation at the Trust.

• Newell-Price succeeds Simon Heller, MD, who held the role for 19 years.

• In remarks accompanying the appointment, Newell-Price emphasizes collaboration across multiple stakeholder groups, including patients, staff, the public, industry, universities, charities, and other stakeholders, with the aim of ensuring that research and innovation translate into tangible benefits for patients in the region and beyond.
• The statement underscores a shared foundation of clinical excellence, collaboration, and innovation as the bedrock of the Trust’s research agenda under his direction.

• The new role involves driving forward the Trust’s research and innovation strategy and shaping its alignment with national health planning priorities, including prevention-oriented and treatment-oriented initiatives supported by emerging technologies and therapeutics.
• As CRIO co-leader, Newell-Price is positioned to influence governance, program development, and integration of translational research within clinical endocrine services and beyond.

• The piece does not report specific metrics, timelines, or outcome data related to the appointment or to anticipated program milestones.
• There is no detail on the exact structure, funding allocations, or performance indicators for the CRIO under his leadership.

• How the CRIO will operationalize the integration of research with routine clinical service in practice at Sheffield, including governance, accountability, and cross-department collaborations, remains to be seen.
• The precise scope of new research and innovation initiatives envisioned under the 10 Year Health Plan within this Trust, and how they will interact with national guidelines, is not detailed in the source.